Research programme: antimicrobial therapeutics - Novoclem Therapeutics/University of North Carolina

Drug Profile

Research programme: antimicrobial therapeutics - Novoclem Therapeutics/University of North Carolina

Latest Information Update: 25 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novoclem Therapeutics; University of North Carolina at Chapel Hill
  • Developer Novoclem Therapeutics
  • Class
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 11 Apr 2017 Preclinical development in Bacterial infections in USA
  • 11 Apr 2017 Novoclem Therapeutics announces intention to submit IND to US FDA in 2018
  • 11 Apr 2017 Novoclem Therapeutics plans a phase I trial in USA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top